Exploring Interventional Radiology: New Advances and Prospects

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1477

Special Issue Editor


E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

This Special Issue of the Journal of Personalized Medicine is dedicated to interventional radiologists (IRs) seeking to showcase cutting-edge techniques, innovative approaches, and emerging challenges within the field of interventional radiology. We invite contributions that not only focus on novel treatments but also offer broader perspectives on the evolution and future of IR as a specialty.

The scope of this Special Issue is not limited to therapeutic advancements. It encourages interdisciplinary and transversal contributions that address the holistic development of interventional radiology, including epidemiological studies, economic evaluations, and strategies for tackling the challenges facing the specialty today. We welcome research articles or reviews that provide new insights into optimizing clinical practice, as well as broader discussions on how to advance IR in a rapidly changing healthcare landscape.

This Special Issue aims to serve as a platform for the IR community to share knowledge, explore new perspectives, and collectively shape the future of interventional radiology.

Prof. Dr. Julien Frandon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional radiology
  • embolization
  • innovative techniques
  • minimally invasive procedures
  • long-term safety
  • prostate cancer
  • vascular anomalies
  • clinical outcomes
  • health economics
  • epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

13 pages, 1881 KiB  
Systematic Review
Percutaneous Magnetic Resonance Imaging-Guided Focal Laser Ablation (MRI-FLA) of Prostate Tumors: A Systematic Review and Network Meta-Analysis
by Clément Marcelin, Clément Klein, Grégoire Robert, Franck Bladou, Nicolas Grenier and Eva Jambon
J. Pers. Med. 2024, 14(12), 1146; https://doi.org/10.3390/jpm14121146 - 10 Dec 2024
Viewed by 1094
Abstract
Background/Objectives: MRI-guided focal laser ablation (MRI-FLA) is an emerging minimally invasive technique for treating localized prostate tumors, aiming to provide effective cancer control while minimizing side effects. This meta-analysis systematically evaluates the clinical outcomes, technical efficacy, and complication rates associated with MRI-FLA to [...] Read more.
Background/Objectives: MRI-guided focal laser ablation (MRI-FLA) is an emerging minimally invasive technique for treating localized prostate tumors, aiming to provide effective cancer control while minimizing side effects. This meta-analysis systematically evaluates the clinical outcomes, technical efficacy, and complication rates associated with MRI-FLA to better understand its therapeutic potential and safety profile in prostate cancer management. Methods: In July 2024, PubMed (MEDLINE) was searched for eligible trials using the PRISMA guidelines. The primary outcome was residual disease (RD). The secondary outcomes were technical efficacy, progression to metastatic disease, cancer-specific mortality, complications, and decreases in the prostate-specific antigen (PSA) level. Results: Nine clinical trials involving 296 patients with prostate tumors treated via MRI-FLA were analyzed. A random effects model showed that the overall RD prevalence after ablation was 20.37% (12.56–29.28%; p = 0.03) and the cancer-free survival rate was 75.62% (64.88–85.10%). The rate of major and minor adverse effects was 14.26% (0.61–37.3%, p < 0.01). Conclusions: MRI-FLA is safe, feasible, and effective, although further trials are required. Full article
(This article belongs to the Special Issue Exploring Interventional Radiology: New Advances and Prospects)
Show Figures

Figure 1

Back to TopTop